MedTrace Logo

NCCH2006/MK010 Trial (FORTUNE Trial)

NCT04962867 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2025-10-03

No results posted yet for this study

Summary

This is a single-arm, open-label, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of E7090 in patients with advanced or recurrent solid tumors harboring FGFR genetic alterations (including fusion, mutation, amplification).

Conditions

  • Advanced or Recurrent Solid Tumors
  • FGFR Gene Alterations

Interventions

DRUG

E7090

140 mg of E7090 is orally administered once daily.

Sponsors & Collaborators

  • Eisai Co., Ltd.

    collaborator INDUSTRY

  • National Cancer Center, Japan

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2028-03-31
Completion
2028-03-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04962867 on ClinicalTrials.gov